These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37899444)

  • 21. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
    Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
    Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators.
    Spayne J; Hesketh T
    BMJ Open; 2021 Sep; 11(9):e052016. PubMed ID: 34475188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014.
    Ladner J; Besson MH; Audureau E; Rodrigues M; Saba J
    BMC Health Serv Res; 2016 Oct; 16(1):575. PubMed ID: 27737666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The vaccine and cervical cancer screen (VACCS) project: acceptance of human papillomavirus vaccination in a school-based programme in two provinces of South Africa.
    Botha MH; van der Merwe FH; Snyman LC; Dreyer G
    S Afr Med J; 2015 Jan; 105(1):40-3. PubMed ID: 26046162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Facilitators and barriers of human papillomavirus vaccine uptake in young females 18-26 years old in Singapore: A qualitative study.
    Lim ASE; Lim RBT
    Vaccine; 2019 Sep; 37(41):6030-6038. PubMed ID: 31473002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adolescent girls' recommendations for the design of a human papillomavirus vaccination program in Sindh, Pakistan: a qualitative study.
    Ali RF; Arif Siddiqi D; Mirza A; Naz N; Abdullah S; Kembhavi G; Tam CC; Offeddu V; Chandir S
    Hum Vaccin Immunother; 2022 Nov; 18(5):2045856. PubMed ID: 35240928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leveraging health infrastructure to optimize HPV vaccination for adolescents in Zambia: Protocol for an implementation study.
    Miti S; Shato T; Asante C; Baumann A; Chongwe G; Bobo PM; Silver MI; Hunleth JM
    PLoS One; 2023; 18(5):e0285031. PubMed ID: 37159471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of a national school-based Human Papillomavirus (HPV) vaccine campaign in Fiji: knowledge, vaccine acceptability and information needs of parents.
    La Vincente SF; Mielnik D; Jenkins K; Bingwor F; Volavola L; Marshall H; Druavesi P; Russell FM; Lokuge K; Mulholland EK
    BMC Public Health; 2015 Dec; 15():1257. PubMed ID: 26684658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.
    Mphuru A; Li AJ; Kyesi F; Mwengee W; Mazige F; Nshunju R; Shayo B; Giattas MR; Loharikar A; Lyimo D
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A2-A9. PubMed ID: 33962839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
    Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
    Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis.
    Prem K; Choi YH; Bénard É; Burger EA; Hadley L; Laprise JF; Regan MC; Drolet M; Sy S; Abbas K; Portnoy A; Kim JJ; Brisson M; Jit M
    BMC Med; 2023 Aug; 21(1):313. PubMed ID: 37635227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis.
    Bonjour M; Charvat H; Franco EL; Piñeros M; Clifford GM; Bray F; Baussano I
    Lancet Public Health; 2021 Jul; 6(7):e510-e521. PubMed ID: 33864738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
    Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
    BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Access and Attitudes to HPV Vaccination amongst Hard-To-Reach Populations in Kenya.
    Watson-Jones D; Mugo N; Lees S; Mathai M; Vusha S; Ndirangu G; Ross DA
    PLoS One; 2015; 10(6):e0123701. PubMed ID: 26115523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HPV vaccine acceptance and hesitancy - lessons learned during 8 years of regional HPV prophylaxis program in Wroclaw, Poland.
    Ludwikowska KM; Biela M; Szenborn L
    Eur J Cancer Prev; 2020 Jul; 29(4):346-349. PubMed ID: 31770346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Misinformation Drives Low Human Papillomavirus Vaccination Coverage in South African Girls Attending Private Schools.
    Milondzo T; Meyer JC; Dochez C; Burnett RJ
    Front Public Health; 2021; 9():598625. PubMed ID: 33681125
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.